Skip to main content

Assembly Biosciences, Inc.

corporate_fare Company Profile

Assembly Biosciences, Inc.

ASMB·NASDAQ·Life Sciences·CIK 0001426800

This biotechnology company develops innovative therapies for serious viral diseases. Its pipeline includes several clinical-stage investigational therapies. These include two long-acting helicase-primase inhibitors (HPIs) for recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the hepatitis B virus (HBV) replication cycle. The company also has a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for transplant-related herpesviruses, which is currently undergoing studies to enable a regulatory filing, and additional research programs targeting multiple antiviral targets. In December 2025, Gilead Sciences, Inc. (Gilead) licensed the company's HPI program for recurrent genital herpes, including investigational candidates ABI-1179 (1179) and ABI-5366 (5366), as part of their collaboration. The company's strategy focuses on using its virology research and development expertise to discover and advance next-generation therapeutics for areas with high unmet medical need. Current activities include transitioning the HPI program (5366 and 1179) to Gilead and deciding on a Profit-Share option. For HDV, the company is completing Phase 2 preparation activities and studies for ABI-6250 (6250), with Phase 2 initiation expected in the fourth quarter of 2026. For HBV, the company is evaluating partnering opportunities for ABI-4334 (4334) and has initiated a structured process to find potential partners.

Assembly Biosciences, Inc. (NASDAQ:ASMB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for ASMB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ASMB spans 8-K, SCHEDULE 13D/A, 424B5, 10-Q.

Recent high-impact activity:

  • Assembly Bio Q3 Loss Widens to $20.3M; Gilead $75M Fee Extends Runway Into 2029
  • Assembly Bio Posts $20.3M Q3 Loss, Secures $75M Gilead Fee and 2029 Runway
  • Assembly Bio's ABI-6250 Shows Clean Safety and Target Engagement in Phase 1a
  • Assembly Bio Exercises Profit-Share Option on Gilead Herpes Program, Secures $75M Payment
  • Assembly Bio Q2 Loss Narrows to $3.9M; Cash Runway Extended into 2029

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$72.3M
Net Income
-$6.12M
Diluted EPS
-$0.55
Op. Cash Flow
-$41.09M
Free Cash Flow
-$41.16M
Operating Income
-$12.12M
Cash & Equivalents
$58.45M
Debt / Equity
0.00×
Net Margin
-8.5%
Shares Outstanding
15.86M sh
Source: 10-K · filed 2026-03-19 · accession 0001193125-26-115992

Short Interest & Short Volume

17.00 days to cover

FINRA reported short interest of 3,032,675 shares in ASMB as of the October 30, 2026 settlement, a 4.1% increase from the prior period — about 17.0 days to cover at its recent average daily volume. On November 20, 2026, 68.4% of ASMB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,032,675 shares as of October 30, 2026
Change vs prior period▲ 4.1%
Days to cover17.00 at avg daily volume of 178,424
Daily short volume (FINRA facilities)68.4% of 183,177 shares on November 20, 2026
5-day average short volume59.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$22.19
52-week range · as of 2026-11-12 $19.2 – $39.7
Market cap
$454.39M
Volume
480.9K (1.8× avg)
3-mo avg 269.6K
Live data · 2026-11-21 19:10 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ASMB - Latest Insights

ASMB
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.95
Real-time Price: $22.19 info
Change: +$2.24 (+11%) info
Market Cap: $454.39M info
ASMB
Nov 12, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $20.19
Real-time Price: $22.19 info
Change: +$2.00 (+10%) info
Market Cap: $454.39M info
ASMB
Oct 05, 2026, 10:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.79
Real-time Price: $22.19 info
Change: -$0.595 (-3%) info
Market Cap: $454.39M info
ASMB
Sep 08, 2026, 4:49 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $36.00
Real-time Price: $22.19 info
Change: -$13.81 (-38%) info
Market Cap: $454.39M info
ASMB
Aug 13, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.95
Real-time Price: $22.19 info
Change: -$7.76 (-26%) info
Market Cap: $454.39M info
ASMB
Jun 05, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.85
Real-time Price: $22.19 info
Change: -$0.660 (-3%) info
Market Cap: $454.39M info
ASMB
May 27, 2026, 8:51 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $27.40
Real-time Price: $22.19 info
Change: -$5.21 (-19%) info
Market Cap: $454.39M info
ASMB
May 26, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.75
Real-time Price: $22.19 info
Change: -$6.56 (-23%) info
Market Cap: $454.39M info
ASMB
May 26, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.75
Real-time Price: $22.19 info
Change: -$6.56 (-23%) info
Market Cap: $454.39M info
ASMB
May 22, 2026, 7:39 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $29.00
Real-time Price: $22.19 info
Change: -$6.81 (-23%) info
Market Cap: $454.39M info
ASMB
May 22, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.92
Real-time Price: $22.19 info
Change: -$4.73 (-18%) info
Market Cap: $454.39M info
ASMB
May 22, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $26.92
Real-time Price: $22.19 info
Change: -$4.73 (-18%) info
Market Cap: $454.39M info
ASMB
May 07, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.68
Real-time Price: $22.19 info
Change: -$8.49 (-28%) info
Market Cap: $454.39M info
ASMB
May 07, 2026, 4:10 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $30.68
Real-time Price: $22.19 info
Change: -$8.49 (-28%) info
Market Cap: $454.39M info
ASMB
Apr 22, 2026, 4:22 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $28.30
Real-time Price: $22.19 info
Change: -$6.11 (-22%) info
Market Cap: $454.39M info
ASMB
Apr 22, 2026, 4:12 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $28.30
Real-time Price: $22.19 info
Change: -$6.11 (-22%) info
Market Cap: $454.39M info
ASMB
Mar 19, 2026, 5:04 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $28.00
Real-time Price: $22.19 info
Change: -$5.81 (-21%) info
Market Cap: $454.39M info
ASMB
Mar 19, 2026, 4:15 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $28.20
Real-time Price: $22.19 info
Change: -$6.01 (-21%) info
Market Cap: $454.39M info
ASMB
Mar 19, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.40
Real-time Price: $22.19 info
Change: -$6.21 (-22%) info
Market Cap: $454.39M info
ASMB
Mar 19, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.40
Real-time Price: $22.19 info
Change: -$6.21 (-22%) info
Market Cap: $454.39M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets